Source: Eur Respir Mon; 2003: 27: 33–56
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Delcroix, N.W. Morrell, M. Abramowicz, O. Sitbon, A. Boonstra, N. Galie, E. Grünig, P. Hervé, R.C. Trembath, A.J. Peacock, M.M. Hoeper, and the other participants of the working group “Pulmonary arterial hypertension”. Pulmonary arterial hypertension: genetics, reversibility testing and follow-up. Eur Respir Mon; 2003: 27: 33–56

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension Source: Eur Respir Rev 2013; 22: 20-25 Year: 2013 A USA-based registry for pulmonary arterial hypertension: 1982 2006 Source: Eur Respir J 2007; 30: 1103-1110 Year: 2007 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension Source: Eur Respir J 2012; 40: 1410-1419 Year: 2012 Pathophysiology of exercise limitation in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Survival in pulmonary hypertension in Spain: insights from the Spanish registry}, Source: Eur Respir J 2012; 40: 596-603 Year: 2012 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Characteristics of a stable and satisfactory condition in long term survivors of pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Update on current treatment options of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 End points in pulmonary arterial hypertension: the way forward Source: Eur Respir J 2004; 23: 947-953 Year: 2004 A new molecular genetic diagnostic approach for pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Clinical meaning of low DLCO in idiopathic pulmonary arterial hypertension (IPAH) - Prospective single centre study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Early detection and management of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 306-312 Year: 2012 Simple, non-invasive methods to assess severity of pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 A critical analysis of survival in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:218-222 Year: 2012